Balanced news tone
News Sentiment
ALVO sentiment intelligence
Alvotech news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
85/100 classification confidence.
directly relevant articles
high-authority source matches
-9.1% over one week, -21.3% over four weeks, trend inactive, and below fair value.
Alvotech (ALVO) Could Be 76% Below Fair Value On New $75 Million Debt Facility
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Alvotech (ALVO): 10 Penny Stocks With Explosive Growth Potential
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 20 Jun 2026 07:00
- Source
- Market source
Alvotech Closes $98 Million Share Offering
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 10:34
- Source
- MT Newswires
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 09:51
- Source
- GlobeNewswire
Alvotech seeks $125M in shares for biosimilar development
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Stock Titan
Alvotech (NASDAQ: ALVO) secures $165M through share sale and private placement
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Stock Titan
Biotech Alvotech aims to raise up to $165M for biosimilar pipeline
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- Stock Titan
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- GlobeNewswire
Alvotech seeks $125M to fund biosimilar medicines via share sale
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- Stock Titan
Alvotech (ALVO) Returns To Quarterly Profitability Challenging Concern Over Persistent Losses
- Tone
- Negative 18/100
- Event
- Market update
- Published
- 10 Jun 2026 07:00
- Source
- simplywall.st
Alvotech gains on FDA acceptance of Entyvio biosimilar BLA (ALVO:NASDAQ)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- Seeking Alpha
Alvotech shares jump after FDA accepts Entyvio biosimilar application for review (ALVO)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- Market source
Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 07:00
- Source
- Market source
Biotech Alvotech joins Jefferies, Goldman Sachs, UBS investor talks
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Stock Titan
Alvotech and Islandsbanki Renew Market Making Agreement to Enhance Share Liquidity on Nasdaq Iceland
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 01 Jun 2026 07:00
- Source
- Quiver Quantitative
Alvotech Q1 Earnings Call Highlights
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- MarketBeat
Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 06 May 2026 07:00
- Source
- Market source
Alvotech (NASDAQ:ALVO) Q1 2026 Results Miss Estimates, Shares Drop Over 9% as Revenue and EPS Fall Short
- Tone
- Negative 18/100
- Event
- Earnings
- Published
- 06 May 2026 07:00
- Source
- ChartMill
Alvotech (ALVO) Valuation Gap Under Review After Mixed Share Performance And Biosimilar Pipeline Progress
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Here’s What the Street Thinks About Alvotech (ALVO)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Apr 2026 07:00
- Source
- Market source
Alvotech: Improving Fundamentals Signal Potential Bottom For This Biosimilar Player (ALVO)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Apr 2026 07:00
- Source
- Seeking Alpha
Is There Now an Opportunity in Alvotech (ALVO) After a 64% One-Year Share Price Slide?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Feb 2026 08:00
- Source
- simplywall.st
Is Alvotech (ALVO) Pricing Make Sense After A 64% One Year Share Price Slump
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 16 Feb 2026 08:00
- Source
- Market source
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Dec 2025 08:00
- Source
- Market source
Alvotech's (NASDAQ:ALVO) 31% Dip In Price Shows Sentiment Is Matching Revenues
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Nov 2025 08:00
- Source
- simplywall.st
Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Sep 2025 07:00
- Source
- Market source